- Home
- PAYO vs IRON Comparison
PAYO vs IRON Comparison
Compare PAYO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- IRON
- Stock Information
- Founded
- PAYO 2005
- IRON 2017
- Country
- PAYO United States
- IRON United States
- Employees
- PAYO N/A
- IRON N/A
- Industry
- PAYO EDP Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- IRON Health Care
- Exchange
- PAYO Nasdaq
- IRON Nasdaq
- Market Cap
- PAYO 2.1B
- IRON 2.1B
- IPO Year
- PAYO N/A
- IRON N/A
- Fundamental
- Price
- PAYO $5.25
- IRON $88.83
- Analyst Decision
- PAYO Strong Buy
- IRON Strong Buy
- Analyst Count
- PAYO 8
- IRON 13
- Target Price
- PAYO $10.06
- IRON $106.92
- AVG Volume (30 Days)
- PAYO 2.7M
- IRON 601.7K
- Earning Date
- PAYO 11-05-2025
- IRON 11-07-2025
- Dividend Yield
- PAYO N/A
- IRON N/A
- EPS Growth
- PAYO N/A
- IRON N/A
- EPS
- PAYO 0.18
- IRON N/A
- Revenue
- PAYO $1,039,820,000.00
- IRON N/A
- Revenue This Year
- PAYO $9.64
- IRON N/A
- Revenue Next Year
- PAYO $7.37
- IRON N/A
- P/E Ratio
- PAYO $29.58
- IRON N/A
- Revenue Growth
- PAYO 10.58
- IRON N/A
- 52 Week Low
- PAYO $4.92
- IRON $30.82
- 52 Week High
- PAYO $11.29
- IRON $95.95
- Technical
- Relative Strength Index (RSI)
- PAYO 28.70
- IRON 65.91
- Support Level
- PAYO $4.92
- IRON $83.01
- Resistance Level
- PAYO $5.87
- IRON $87.50
- Average True Range (ATR)
- PAYO 0.20
- IRON 3.26
- MACD
- PAYO -0.04
- IRON -0.40
- Stochastic Oscillator
- PAYO 25.56
- IRON 68.20
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.